SCHEDULE: Intracoastal Capital, Kopin, Asher Maintain 4.99% Stake in PharmaCyte

Intracoastal Capital LLC, Mitchell P. Kopin, and Daniel B. Asher report a continued passive beneficial ownership of 4.99% in PharmaCyte Biotech, Inc. as of December 31, 2025, constrained by blocker provisions.

Summary

• Intracoastal Capital LLC and Mitchell P. Kopin beneficially own 532,254 shares of PharmaCyte Biotech, Inc. common stock, representing 4.99% of the class.
• Daniel B. Asher beneficially owns 531,086 shares of PharmaCyte Biotech, Inc. common stock, also representing 4.99% of the class.
• This ownership includes shares issuable upon exercise of warrants (Intracoastal Warrant 1 and Intracoastal Warrant 2).
• The reported percentages are capped at 4.99% due to "blocker provisions" in multiple warrants (Intracoastal Warrants 2, 3, 4, 5) and Series H Convertible Preferred Stock, which prevent beneficial ownership from exceeding this threshold.
• Without these blocker provisions, Intracoastal Capital and Mr. Kopin would beneficially own 14,934,167 shares, and Mr. Asher would beneficially own 14,956,394 shares.
• The calculation is based on 10,134,160 shares of Common Stock outstanding as of December 16, 2025, as reported by the Issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-slightly positive update, confirming continued passive institutional interest without any immediate red flags, though the significant unexercised/unconverted shares due to blockers introduce a potential future dilution factor.

Positives

• Continued significant passive investment by institutional and individual investors, indicating a long-term interest in the company.
• The presence of blocker provisions suggests a strategic approach by the investors to avoid triggering certain regulatory thresholds (e.g., 5% ownership requiring a Schedule 13D filing, which implies intent to influence control).

Negatives

• The blocker provisions prevent the full exercise of warrants and conversion of preferred stock, potentially limiting the company's ability to fully realize capital from these instruments if the holders choose not to exceed the 4.99% threshold.

Risks

• The existence of substantial unexercised warrants and unconverted preferred stock (totaling over 14 million shares if not for blockers) represents potential future dilution if these instruments are eventually exercised/converted beyond the current 4.99% limit, or if the blocker provisions are waived or modified.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding PharmaCyte Biotech, Inc.'s operational or financial performance.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for passive institutional investors in the biotechnology sector, indicating a long-term, non-controlling interest in companies with potential for growth. The use of blocker provisions is a standard mechanism to manage regulatory reporting requirements while maintaining significant investment exposure.

Stakeholder Impact

• Shareholders: The continued passive investment by these entities may be viewed as a vote of confidence, but the large number of unexercised warrants and unconverted preferred stock (if blockers were removed) represents potential future dilution.

Key Dates

Recommendation

The filing is a routine Schedule 13G amendment, indicating a passive, non-controlling stake by institutional investors. It does not provide new operational or financial information to warrant a change in investment thesis. The significant number of shares held via warrants and convertible preferred stock, though currently capped by blocker provisions, represents a potential future overhang or dilution risk if these provisions are ever removed or the shares are fully exercised/converted.

Keywords

PharmaCyte Biotech, PMCB, Intracoastal Capital, Mitchell P. Kopin, Daniel B. Asher, Schedule 13G, Beneficial Ownership, Warrants, Preferred Stock, Biotechnology, SEC Filing, Institutional Investor